IQI - Incannex full steam ahead towards sleep apnoea trial
(NewsDirect)
Incannex HealthcareLtd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakleyspeaks with Proactive after the company received clearance from the USFood and Drug Administration (FDA) to begin the Phase 2/3 clinicaltrial for its IHL-42X asset, designed to address obstructive sleepapnoea (OSA).
Theclinical-stage pharmaceutical company developing proprietary medicinalcannabinoid products and psychedelic-assisted psychotherapies forunmet needs received the approval after submitting an InvestigationalNew Drug (IND) application to the FDA last month. With the milestoneapproval in the bag, Incannex will proceed with the finalisation ofinstitutional review board applications and submissions for the leadclinical trial sites.
Incannex is developing unique medicinal cannabis pharmaceuticalproducts and psychedelic medicine therapies for the treatment of OSA,traumatic brain injury (TBI) and concussion, lung inflammation (ARDS,COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory boweldisease, anxiety disorders, addiction disorders, and pain, among otherindications.
US FDA approval andregistration, subject to ongoing clinical success, is being pursuedfor each drug and therapy under development.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.